First Exposure

This website will be retired at the end of January 2026. Please download any resources or information sheets you may need before January 30, 2026. Thanks for being part of our community. For more information, please contact info@firstexposure.ca.

Sémaglutide

Sémaglutide (Ozempic®, Rybelsus®, Wegovy®) Date de dernière mise à jour des informations : Novembre 2024 La plupart des grossesses mènent à la naissance de bébés en santé, mais des complications et résultats inattendus peuvent se produire. Ces risques sont appelés risques de base. Au Canada, le risque de base de malformations congénitales majeures se situe entre 3 % […]

Semaglutide

Semaglutide (Ozempic®, Rybelsus®, Wegovy®) Information last updated November 2024 Most pregnancies result in healthy babies, but there are chances of complications and unexpected outcomes. These chances are called baseline risks. In Canada, the baseline risk of major birth defects is 3-5%. This means that 3-5 out of 100 babies born in the general population will […]